{"id":716,"date":"2024-02-07T11:32:57","date_gmt":"2024-02-07T10:32:57","guid":{"rendered":"https:\/\/project.eortc.org\/e2-radiate\/?p=716"},"modified":"2024-02-07T17:13:56","modified_gmt":"2024-02-07T16:13:56","slug":"oligocare-symposium","status":"publish","type":"post","link":"https:\/\/project.eortc.org\/e2-radiate\/2024\/02\/07\/oligocare-symposium\/","title":{"rendered":"Virtual symposium on \u201cHot topics and challenges in SBRT for oligometastatic disease\u201d"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1144px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-title-text fusion-title-size-one\" style=\"--awb-margin-top-small:0px;--awb-margin-right-small:0px;--awb-margin-bottom-small:20px;--awb-margin-left-small:0px;\"><div class=\"title-sep-container title-sep-container-left fusion-no-large-visibility fusion-no-medium-visibility fusion-no-small-visibility\"><div class=\"title-sep sep-double sep-solid\" style=\"border-color:#e0dede;\"><\/div><\/div><span class=\"awb-title-spacer fusion-no-large-visibility fusion-no-medium-visibility fusion-no-small-visibility\"><\/span><h1 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Virtual symposium on \u201cHot topics and challenges in SBRT for oligometastatic disease\u201d<\/h1><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-double sep-solid\" style=\"border-color:#e0dede;\"><\/div><\/div><\/div><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"--awb-flex-grow:0;--awb-flex-grow-medium:0;--awb-flex-grow-small:0;--awb-flex-shrink:0;--awb-flex-shrink-medium:0;--awb-flex-shrink-small:0;width:104% !important;max-width:104% !important;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-0 fusion_builder_column_inner_1_2 1_2 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:50%;--awb-margin-top-large:0px;--awb-spacing-right-large:3.84%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:3.84%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>On 30 January 2024, EORTC and the <a href=\"https:\/\/www.estro.org\/\" target=\"_blank\" rel=\"noopener\">European Society for Radiotherapy and Oncology (ESTRO)<\/a> collaboratively organised a virtual symposium as part of the OligoCare project. Distinguished speakers, including Daniela Greto, Giulio Francolini, Chiaojung Jillian Tsai, David Palma, and Shankar Siva, engaged in discussions on the latest evidence and clinical trials in the oligometastatic disease field, presenting insights derived from the OligoCare cohort. The symposium served as a hub for the exchange of knowledge and expertise among professionals dedicated to advancing the understanding and treatment of oligometastatic disease.<\/p>\n<\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-1 fusion_builder_column_inner_1_2 1_2 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:50%;--awb-margin-top-large:0px;--awb-spacing-right-large:3.84%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:3.84%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-video fusion-youtube\" style=\"--awb-max-width:600px;--awb-max-height:360px;\"><div class=\"video-shortcode\"><div class=\"fluid-width-video-wrapper\" style=\"padding-top:60%;\" ><iframe title=\"YouTube video player 1\" src=\"https:\/\/www.youtube.com\/embed\/cjR2pwsC2RY?wmode=transparent&autoplay=0\" width=\"600\" height=\"360\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture;\"><\/iframe><\/div><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-text fusion-text-2\"><p>The discussions covered various topics, including the application of the TwiCs (Two-Stage Comparison) methodology in radiation oncology. The following ten key takeaways encapsulate the essence of the discussions:<\/p>\n<\/div><ul style=\"--awb-size:21px;--awb-item-padding-bottom:10px;--awb-iconcolor:var(--awb-color4);--awb-line-height:35.7px;--awb-icon-width:35.7px;--awb-icon-height:35.7px;--awb-icon-margin:14.7px;--awb-content-margin:50.4px;--awb-circlecolor:var(--awb-color1);--awb-circle-yes-font-size:18.48px;\" class=\"fusion-checklist fusion-checklist-1 fusion-checklist-default type-icons\"><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>OligoCare Research Opportunities<\/strong>: Partners and researchers within the OligoCare community now have the opportunity to propose and evaluate ideas with the steering committee, opening doors to exciting research prospects.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>Patient Enrolment Milestone<\/strong>: The OligoCare community celebrated the recruitment of over 2500 patients, expressing gratitude for the collective effort driving crucial research forward.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>Tailoring Treatments for Personalized Care<\/strong>: Emphasis on different biological doses based on tumour type and site underscored the importance of personalized care in the treatment of oligometastatic disease.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>Safety as a Top Priority<\/strong>: The symposium reiterated the commitment to safety, with minimal toxicity and complications leading to SBRT-related deaths, emphasizing the paramount importance of patient safety.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>Prostate Cancer Quality of Life (QoL)<\/strong>: Insights revealed that QoL in prostate cancer patients remains stable during the initial 6 months of SBRT for Oligometastatic Disease, empowering patients on their cancer journey.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>Holistic Patient Well-being<\/strong>: Baseline QoL comparability across tumour types emphasized the need for holistic approaches, addressing the overall well-being of patients undergoing treatment.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>ARTO Trial Breakthroughs<\/strong>: The ARTO trial showcased significant advancements with improved biochemical response, progression-free survival (PFS), and time to the next systemic treatment in mCRPC OMD cases.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>STOP Trial Insights<\/strong>: Results from the STOP trial clarified that standard of care (SOC) + SBRT and SBRT yield similar median PFS for oligoprogressive cancer, guiding clinicians in treatment decisions.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>CURB Trial Impact<\/strong>: The CURB trial demonstrated increased PFS with SBRT + standard care, particularly in breast cancer cases, laying the groundwork for future advancements in cancer treatment.<\/p>\n<\/div><\/li><li class=\"fusion-li-item\" style=\"\"><span class=\"icon-wrapper circle-yes\"><i class=\"fusion-li-icon fa-check-circle fas\" aria-hidden=\"true\"><\/i><\/span><div class=\"fusion-li-item-content\">\n<p><strong>SABR Insights for Lung Disease<\/strong>: Exploring SABR for OMD lung disease, the symposium revealed that single vs. multifraction SABR showed no significant impact on results, providing valuable insights for better decision-making in lung cancer treatment.<\/p>\n<\/div><\/li><\/ul><div class=\"fusion-text fusion-text-3\" style=\"--awb-margin-top:20px;\"><p>The EORTC &amp; ESTRO OligoCare symposium was as a pivotal event, bringing together experts and stakeholders to advance the understanding of oligometastatic disease and pioneer new paths in radiation oncology. The <a href=\"https:\/\/youtu.be\/cjR2pwsC2RY\" target=\"_blank\" rel=\"noopener\">video recording<\/a> is now available for viewing.<\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":729,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/comments?post=716"}],"version-history":[{"count":5,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/716\/revisions"}],"predecessor-version":[{"id":734,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/716\/revisions\/734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media\/729"}],"wp:attachment":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media?parent=716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/categories?post=716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/tags?post=716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}